Idroxioleate Sodium for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Dec 2019: Trial started, NCT04250922
  2. 31 Jan 2020: Trial registered, NCT04250922

The trials

NCT04250922: LAM561 With RT and TMZ for Adults With Glioblastoma

State
Under way
Phase
Phase 2 and Phase 3
People
144 taking part
Started
1 Dec 2019
Primary completion
15 Jan 2026
Arms
Arm B: SoC + 12 g/day of LAM561
Results
None posted
  1. 1 Dec 2019: Trial started
  2. 31 Jan 2020: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.